Sonendo Inc. Reports Third Quarter 2021 Financial Results and Issues Full Year 2021 Revenue Guidance
Sonendo, a leading dental technology firm, reported a 29% increase in total revenue for Q3 2021, totaling $7.9 million.
The GentleWave console revenue rose 44% to $1.8 million, while procedure instrument revenue climbed 30% to $3.7 million. Software revenue grew 17% to $1.7 million. The company completed its IPO on November 2, raising approximately $84 million.
For 2021, Sonendo projects total revenue between $32 million and $32.5 million.
- Total revenue increased to $7.9 million, up 29% year-over-year.
- GentleWave console revenue grew 44% to $1.8 million.
- Procedure instrument revenue rose 30% to $3.7 million.
- Software revenue increased by 17% to $1.7 million.
- Achieved 26% gross margin, up from 19.6% year-over-year.
- Successfully raised approximately $84 million in net proceeds from IPO.
- Net loss increased to $12.7 million, compared to $10.6 million in the prior year.
- Total operating expenses rose to $13.1 million, up from $10.8 million.
Recent Highlights
-
Total revenue of
for the third quarter of 2021, representing growth of$7.9 million 29% compared to prior year period -
GentleWave console revenue of
for the third quarter 2021, representing growth of$1.8 million 44% compared to prior year period -
Procedure instrument revenue of
for the third quarter 2021, representing growth of$3.7 million 30% compared to prior year period -
Software revenue of
for the third quarter 2021, representing growth of$1.7 million 17% compared to prior year period -
Completed initial public offering on
November 2 , raising approximately in net proceeds$84 million -
Added
Carolyn Beaver ,Karen McGinnis ,Raj Pudipeddi , andSadie Stern to the Board of Directors -
Issued 2021 full year total revenue guidance range of
to$32.0 million $32.5 million
“We are very pleased with our quarterly results and continue to make great progress on expanding our commercial organization to make GentleWave the standard of care for root canal therapy,” said
Third Quarter 2021 Financial Results
Total Revenue was
Gross Margin for third quarter was
Total operating expenses in the third quarter 2021 were
Net loss was
Cash and cash equivalents as of
2021 Financial Guidance
The fourth quarter is typically Sonendo’s strongest quarter as a large number of endodontists wait to purchase capital equipment to maximize calendar year tax benefits. The Company expects full year 2021 total revenue to be in the range of
Webcast and Conference Call Information
About
Forward Looking Statements
In addition to background and historical information, this press release contains “forward-looking statements” based on Sonendo’s current expectations, forecasts and beliefs. These forward-looking statements are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Actual outcomes and results could differ materially due to a number of factors, including the ongoing uncertainty of the impact of the COVID-19 pandemic, as well as COVID recovery impact, on its business. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its public filings with the
CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) |
||||||||
|
|
|
|
|
||||
|
|
2021 |
|
2020 |
||||
ASSETS |
|
(Unaudited) |
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
13,748 |
|
|
$ |
51,722 |
|
Accounts receivable, net |
|
|
1,914 |
|
|
|
1,934 |
|
Inventory |
|
|
7,050 |
|
|
|
4,338 |
|
Prepaid expenses and other current assets |
|
|
3,357 |
|
|
|
901 |
|
Total current assets |
|
|
26,069 |
|
|
|
58,895 |
|
Property and equipment, net |
|
|
2,527 |
|
|
|
3,153 |
|
Operating lease right-of-use assets |
|
|
2,943 |
|
|
|
3,308 |
|
Intangible assets, net |
|
|
3,122 |
|
|
|
2,208 |
|
|
|
|
8,454 |
|
|
|
8,454 |
|
Other assets |
|
|
115 |
|
|
|
123 |
|
Total assets |
|
$ |
43,230 |
|
|
$ |
76,141 |
|
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,987 |
|
|
$ |
1,930 |
|
Accrued expenses |
|
|
4,290 |
|
|
|
3,247 |
|
Accrued compensation |
|
|
3,391 |
|
|
|
3,714 |
|
Operating lease liabilities |
|
|
935 |
|
|
|
802 |
|
Term loan |
|
|
— |
|
|
|
28,352 |
|
Other current liabilities |
|
|
2,009 |
|
|
|
2,756 |
|
Total current liabilities |
|
|
12,612 |
|
|
|
40,801 |
|
Warrant liabilities |
|
|
4,225 |
|
|
|
1,914 |
|
Operating lease liabilities, net of current |
|
|
1,964 |
|
|
|
2,449 |
|
Term loan, net of current |
|
|
26,374 |
|
|
|
— |
|
Forward obligation |
|
|
3,300 |
|
|
|
2,750 |
|
Other liabilities |
|
|
469 |
|
|
|
776 |
|
Total liabilities |
|
|
48,944 |
|
|
|
48,690 |
|
Commitments and contingencies (Note 8) |
|
|
|
|
|
|
||
Convertible preferred stock |
|
|
281,342 |
|
|
|
281,342 |
|
Stockholders’ deficit: |
|
|
|
|
|
|
||
Common stock |
|
|
2 |
|
|
|
2 |
|
Additional paid-in-capital |
|
|
11,326 |
|
|
|
9,703 |
|
Accumulated deficit |
|
|
(298,333 |
) |
|
|
(263,545 |
) |
|
|
|
(287,005 |
) |
|
|
(253,840 |
) |
Less: |
|
|
(51 |
) |
|
|
(51 |
) |
Total stockholders’ deficit |
|
|
(287,056 |
) |
|
|
(253,891 |
) |
Total liabilities, convertible preferred stock and stockholders’ deficit |
|
$ |
43,230 |
|
|
$ |
76,141 |
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (In thousands, except share and per share data) |
||||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
|
||||||||||||
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
Product revenue |
|
$ |
6,186 |
|
|
$ |
4,675 |
|
|
$ |
18,166 |
|
|
$ |
10,690 |
|
Software revenue |
|
|
1,701 |
|
|
|
1,457 |
|
|
|
5,140 |
|
|
|
3,990 |
|
Total revenue |
|
|
7,887 |
|
|
|
6,132 |
|
|
|
23,306 |
|
|
|
14,680 |
|
Cost of sales |
|
|
5,838 |
|
|
|
4,931 |
|
|
|
17,422 |
|
|
|
12,550 |
|
Gross profit |
|
|
2,049 |
|
|
|
1,201 |
|
|
|
5,884 |
|
|
|
2,130 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative |
|
|
8,495 |
|
|
|
5,802 |
|
|
|
22,400 |
|
|
|
19,423 |
|
Research and development |
|
|
4,633 |
|
|
|
4,920 |
|
|
|
14,310 |
|
|
|
14,551 |
|
Change in fair value of contingent earnout |
|
|
19 |
|
|
|
30 |
|
|
|
12 |
|
|
|
(478 |
) |
Total operating expenses |
|
|
13,147 |
|
|
|
10,752 |
|
|
|
36,722 |
|
|
|
33,496 |
|
Loss from operations |
|
|
(11,098 |
) |
|
|
(9,551 |
) |
|
|
(30,838 |
) |
|
|
(31,366 |
) |
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest and financing cost, net |
|
|
(1,076 |
) |
|
|
(1,080 |
) |
|
|
(3,224 |
) |
|
|
(2,877 |
) |
Change in fair value of warrant liabilities |
|
|
(159 |
) |
|
|
38 |
|
|
|
(176 |
) |
|
|
105 |
|
Change in fair value of forward obligation |
|
|
(400 |
) |
|
|
— |
|
|
|
(550 |
) |
|
|
— |
|
Loss before income tax benefit |
|
|
(12,733 |
) |
|
|
(10,593 |
) |
|
|
(34,788 |
) |
|
|
(34,138 |
) |
Net loss and comprehensive loss |
|
$ |
(12,733 |
) |
|
$ |
(10,593 |
) |
|
$ |
(34,788 |
) |
|
$ |
(34,138 |
) |
Net loss per share attributable to common stock – basic and diluted |
|
$ |
(10.33 |
) |
|
$ |
(8.84 |
) |
|
$ |
(28.54 |
) |
|
$ |
(28.58 |
) |
Weighted-average shares used in computing net loss per share attributable to common stock – basic and diluted |
|
|
1,232,921 |
|
|
|
1,197,919 |
|
|
|
1,218,815 |
|
|
|
1,194,562 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209006018/en/
Investor Contact:
IR@Sonendo.com
Source:
FAQ
What were Sonendo's total revenues for Q3 2021?
How much did Sonendo raise in its recent IPO?
What is Sonendo's revenue guidance for 2021?
What was the net loss for Sonendo in Q3 2021?